Loading...
Loading...
Exelixis, Inc.
EXEL today announced the European Medicines Agency
(EMA) has accepted for review the Marketing Authorization Application (MAA)
for COMETRIQ™ (cabozantinib) for the proposed indication of treatment of
progressive, unresectable, locally advanced, or metastatic medullary thyroid
cancer (MTC). The completion of the MAA validation process confirms that the
submission is sufficient to permit a substantive review for marketing
authorization in the European Union.
The MAA contains data from EXAM, the phase 3 pivotal study of COMETRIQ in
progressive, metastatic MTC. This trial also served as the basis for Exelixis'
New Drug Application with the U.S. Food and Drug Administration (FDA). The FDA
approved COMETRIQ for the treatment of progressive, metastatic MTC on November
29, 2012.
COMETRIQ (cabozantinib) received orphan drug designation in the European Union
from the Committee for Orphan Medicinal Products (COMP) for the treatment of
MTC.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in